Scientific Publications

Latest publication
OKN4395, a first-in-class EP2/EP4/DP1 triple antagonist reprograms prostanoid-driven immunosuppression to restore antitumor immunity
Maximilien Grandclaudon
et al.
bioRxiv
Read details

Browse all publications

OKN4395, a first-in-class EP2/EP4/DP1 triple antagonist reprograms prostanoid-driven immunosuppression to restore antitumor immunity
Maximilien Grandclaudon
et al.
bioRxiv
February 10, 2026